LIFE SCIENCES INC
10KSB, EX-27.1, 2000-09-13
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: LIFE SCIENCES INC, 10KSB, EX-10.19, 2000-09-13
Next: LIFE SCIENCES INC, 10KSB, EX-99.1, 2000-09-13



<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM LIFE
SCIENCES, INC. AND SUBSIDIARY FINANCIAL STATEMENTS AS OF MAY 31, 2000 AND FOR
THE YEAR THEN ENDED AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH LIFE
SCIENCES, INC. AND SUBSIDIARY ANNUAL REPORT ON FORM 10-KSB FOR THE YEAR ENDED
MAY 31, 2000.
</LEGEND>
<MULTIPLIER> 1
<CURRENCY> U.S. DOLLARS

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          MAY-31-2000
<PERIOD-START>                             JUN-01-1999
<PERIOD-END>                               MAY-31-2000
<EXCHANGE-RATE>                                      1
<CASH>                                          41,805
<SECURITIES>                                         0
<RECEIVABLES>                                  267,702
<ALLOWANCES>                                     5,000
<INVENTORY>                                    431,376
<CURRENT-ASSETS>                               749,963
<PP&E>                                       1,181,764
<DEPRECIATION>                                 994,581
<TOTAL-ASSETS>                               1,218,095
<CURRENT-LIABILITIES>                          927,894
<BONDS>                                              0
                                0
                                          0
<COMMON>                                       419,667
<OTHER-SE>                                    (129,466)
<TOTAL-LIABILITY-AND-EQUITY>                 1,218,095
<SALES>                                      1,475,766
<TOTAL-REVENUES>                             1,475,766
<CGS>                                          647,025
<TOTAL-COSTS>                                  647,025
<OTHER-EXPENSES>                               779,421
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               1,342
<INCOME-PRETAX>                                 47,978
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    47,978
<EPS-BASIC>                                        .01
<EPS-DILUTED>                                      .01


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission